(NASDAQ: FBLG) Fibrobiologics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.22%.
Fibrobiologics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast FBLG's revenue for 2028 to be $563,010,676, with the lowest FBLG revenue forecast at $563,010,676, and the highest FBLG revenue forecast at $563,010,676. On average, 1 Wall Street analysts forecast FBLG's revenue for 2029 to be $1,429,790,517, with the lowest FBLG revenue forecast at $1,429,790,517, and the highest FBLG revenue forecast at $1,429,790,517.
In 2030, FBLG is forecast to generate $2,917,316,043 in revenue, with the lowest revenue forecast at $2,917,316,043 and the highest revenue forecast at $2,917,316,043.